Compare ADMA Biologics Inc (ADMA) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Jones Lang LaSalle Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Jones Lang LaSalle Inc trades at $325.01 (market cap $15.43B). The key difference: Jones Lang LaSalle Inc is far larger — about 7.2× ADMA Biologics Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | JLL | |
|---|---|---|
Market Cap | $2.13B | $15.43B |
Sector | Health | Real Estate |
52-Week High | $20.38 | $358.66 |
52-Week Low | $7.60 | $248.95 |
Enterprise Value | $2.20B | $18.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
JLL trades at $332.57, up 1.56% today, with a bullish technical outlook and strong earnings momentum after beating Q1 2026 EPS estimates. Revenue grew to $26.12B in 2025, with net income reaching $792.10M and improving margins. Positive analyst sentiment includes a $405.50 consensus price target, and recent news highlights strategic growth initiatives and inclusion on Zacks Strong Buy lists as of June 2026.
The stock presents a favorable risk-reward profile with a 22% upside to the consensus target, supported by robust cash flow generation and debt reduction. Key risks include economic sensitivity and competitive pressures, but institutional backing and consistent earnings beats underpin a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
